Immunome (IMNM) Revenue (2023 - 2025)

Immunome (IMNM) has 3 years of Revenue data on file, last reported at $4.0 million in Q2 2025.

• Quarterly Revenue rose 69.84% year-over-year to $4.0 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 63.29% YoY) and the FY2025 annual result came in at $6.9 million, down 23.23% from the prior year.
• Revenue rose to $4.0 million in Q2 2025, from $2.9 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $4.3 million in Q2 2023 to a low of $1.0 million in Q1 2024.
• A 3-year average of $3.0 million and a median of $2.9 million in 2024 frame the typical range for Revenue.
• Annual changes were most pronounced in 2024 — Revenue sank 56.47% — and 2025, when it soared 184.35%.
• Tracing IMNM's Revenue over 3 years: stood at $3.8 million in 2023, then slipped by 28.44% to $2.7 million in 2024, then surged by 46.64% to $4.0 million in 2025.
• The last three Revenue figures came in at $4.0 million (Q2 2025), $2.9 million (Q1 2025), and $2.7 million (Q4 2024), per Business Quant data.